N1-(3,5-difluorophenyl)-N3-nitrile-guanidine | 323589-49-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1-(3,5-difluorophenyl)-N3-nitrile-guanidine
• 英文别名: N''-cyano-N-(3,5-difluorophenyl)guanidine
• CAS: 323589-49-7
• 化学式: C₈H₆F₂N₄
• 分子量: 196.16
• InChiKey: ZPBMOEHLBKFIFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[1-(1H-苯并三唑-1-基)-2,2-二甲基丙基]-3,4-二甲氧基苯乙酰胺 、 N1-(3,5-difluorophenyl)-N3-nitrile-guanidine 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 10.0h， 生成 N-[1-({(cyanoimino)[(3,5-difluorophenyl)amino]methyl}amino)-2,2-dimethylpropyl]-2-(3,4-dimethoxyphenyl)acetamide
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848
• 作为产物：
  描述：

  3,5-二氟苯胺 、 sodium dicyanamide 在 盐酸 作用下， 以 水 为溶剂， 生成 N1-(3,5-difluorophenyl)-N3-nitrile-guanidine
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848

文献信息

• Potassium channel openers
  申请人：——

  公开号：US20020028836A1

  公开（公告）日：2002-03-07

  Compounds of formula I: 1 are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

  公式I的化合物： 1 在治疗通过或用钾通道开放剂预防或改善的疾病中是有用的。还公开了钾通道开放组合物以及在哺乳动物中开放钾通道的方法。
• [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2015003640A1

  公开（公告）日：2015-01-15

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文描述的化合物。
• [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2013102431A1

  公开（公告）日：2013-07-11

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文所述的化合物。
• THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  申请人：Konteatis Zenon D.

  公开号：US20150018328A1

  公开（公告）日：2015-01-15

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文所述的化合物。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US20160318903A1

  公开（公告）日：2016-11-03

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  提供了用于治疗癌症的化合物和治疗癌症的方法，包括向需要治疗的受试者给予此处所描述的化合物。